A Global Health Tidal Wave? Cardiorenal Metabolic Syndrome

Join Drs Nihar Desai and Chiadi Ndumele as they define and discuss cardiorenal metabolic syndrome, a chronic health condition with the potential to impact up to 90% of the US population.
Relevant disclosures can be found with the episode show notes on Medscape www.medscape.com/viewarticle/.... The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association pubmed.ncbi.nlm.nih.gov/37807...
American Heart Association PREVENTTM Online Calculator professional.heart.org/en/gui...
Prevalence of Cardiovascular-Kidney-Metabolic Syndrome Stages in US Adults, 2011-2020 pubmed.ncbi.nlm.nih.gov/38717...
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines pubmed.ncbi.nlm.nih.gov/24222...
Renoprotection With SGLT2 Inhibitors in Type 2 Diabetes Over a Spectrum of Cardiovascular and Renal Risk pubmed.ncbi.nlm.nih.gov/33222...
Cardiovascular and Kidney Outcomes With Finerenone in Patients With Type 2 Diabetes and Chronic Kidney Disease: The FIDELITY Pooled Analysis pubmed.ncbi.nlm.nih.gov/35023...
Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone on Morbidity (Events Indicating Disease Worsening) & Mortality (Death Rate) in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40% (FINEARTS-HF) classic.clinicaltrials.gov/ct...
Novo Nordisk Will Stop the Once-Weekly Injectable Semaglutide Kidney Outcomes Trial, FLOW, Based on Interim Analysis www.novonordisk.com/news-and-...
Long-Term Kidney Outcomes of Semaglutide in Obesity and Cardiovascular Disease in the SELECT Trial pubmed.ncbi.nlm.nih.gov/38796...